Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:

Dar El Oyoun Hospital

Status: Completed

Conditions: Diabetic Macular Edema

Treatments: Drug: Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:

Study type: Observational

Funder types: Other

Identifiers

NCT05847088

N-21-2023

Details and patient eligibility

About

We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing our results , evaluating both anatomical and functional outcomes of DEX therapy for refractory DME.

Full description

Our study aims at evaluating both anatomical and functional outcomes of DEX therapy for cases of refractory DME, with both a single injection, and /or with retreatments.

Enrollment: 58 patients

Sex: All

Ages: 16 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age: 16 or older (Adults)

  • Sex: both
  • NTDME with CMT >300 u
  • < 10% reduction in CMT (than previous treatment)
  • < 50 u reduction in CMT (than previous treatment)
  • Worsening of BCVA > 1 line on E chart.
  • Duration since Previous treatment is: 3 months with DEX, 1 month with Anti-VEGF
  • Pseudophakic eyes
  • NPDR , PRP-treated PDR

Exclusion criteria

• • Phakic eyes

  • Uncontrolled Glaucoma (IOP > 24 mmHg, or cup disc ratio 0.8 or more)
  • Herpetic viral infection.
  • Untreated PDR